Scientists in the United States have developed an experimental "super vaccine" that, in early tests, stopped cancer from forming and spreading in mice. Published in Cell Reports Medicine, the study shows the nanoparticle-based jab uses antigens to help the body recognise cancer and adjuvants to activate the immune system. In trials, 80% of vaccinated mice remained tumour-free for 250 days, while unvaccinated ones died within 35 days. The vaccine also prevented cancer from reaching other organs. Human trials have not yet begun and are years away, but this approach could make cancer prevention possible long before the disease develops.